Effects Of Multi-strain Probiotics Research Articles

The effects of multi-strain probiotics in patients with obesity and metabolic syndrome

The effects of multi-strain probiotics in patients with obesity and metabolic syndrome

Effect of multi-strain probiotics on the growth, hematological profile, blood biochemistry, antioxidant capacity, and physiological responses of Clarias batrachus fingerlings

Effect of multi-strain probiotics on the growth, hematological profile, blood biochemistry, antioxidant capacity, and physiological responses of Clarias batrachus fingerlings

Effect of multi-strain probiotics on the performance of AA+ male broilers.

The aim of the experiment was to investigate the effects of a probiotic complex (PC) consisting of Bacillus subtilis, Clostridium butyricum and Enterococcus faecalis on productive performance, carcass traits, immune organ indices, fecal microbiota counts and noxious gas emissions in AA+ male broilers. Three hundred and sixty 1-day-old AA+ male broilers with similar body weight (44.77 ± 0.25) were randomly divided into 3 treatment groups of 6 replicates each, with 20 broilers in each replicate. The experimental groups consisted of a group fed a basal diet and groups fed basal diet supplemented with 0.1 and 0.2% PC. The results showed that the addition of PC had no significant effect (P > 0.05) on growth performance, and carcass traits of AA+ broilers during the experimental period (1-42 days of age). Dietary addition of PC significantly increased the thymus index of AA+ broilers (P < 0.05), reduced the number of E. coli and Salmonella in feces (P < 0.01) and reduced the concentrations of fecal NH3 and H2S emissions (P < 0.01). Furthermore, birds fed 0.2% PC diet had the highest number of fecal Lactobacillus counts. Results indicate that probiotic complex consisting of Bacillus subtilis, Clostridium butyricum and Enterococcus faecalis enhances immune organ development, reduces the number of E. coli and Salmonella in feces, increases the number of Lactobacillus and reduces NH3 and H2S emissions in feces. This trial provides a theoretical basis for the use of probiotic complexes in broiler production.

The effect of multistrain probiotics on functional constipation in the elderly: a randomized controlled trial

Background and objectivesConstipation is one of the most common gastrointestinal conditions, particularly among older individuals. This study aimed to evaluate the efficacy and safety of selected multistrain probiotics on functional constipation and laboratory blood parameters in the elderly living in a nursing home.Subjects and methodsSixty participants (42 females and 18 males) aged 77.9 ± 8.84 years with functional constipation, who met the eligibility criteria, completed the study. In a double-blind, placebo-controlled, parallel design, each participant was randomized to receive either the selected probiotic mixture (N = 28) or placebo (N = 32) for 12 weeks as an adjunct to their usual diet and medications. The liquid probiotic formulation containing Bifidobacterium animalis subsp. lactis BLC1, Lactobacillus acidophilus LA3 and Lactobacillus casei BGP93 was tested for the first time.ResultsSupplementation of selected probiotics resulted in a slight but nonsignificant increase in cumulative stool frequency compared with placebo. However, after the 71st day of the treatment, the cumulative number of stools was significantly higher in the probiotic group (P < 0.05) when the influence of laxative was excluded. The trend towards an increase in the difference between the two groups, which began 1 week after the probiotic intervention, pointed out to their prolonged effect. There were no significant dependent or independent effects of treatment and time on most of the 27 laboratory blood parameters tested.ConclusionsMultistrain probiotic supplementation was found to be efficacious, safe and well tolerated in the elderly with functional constipation.

AB-Kefir Reduced Body Weight and Ameliorated Inflammation in Adipose Tissue of Obese Mice Fed a High-Fat Diet, but Not a High-Sucrose Diet.

Consumption of different types of high-calorie foods leads to the development of various metabolic disorders. However, the effects of multi-strain probiotics on different types of diet-induced obesity and intestinal dysbiosis remain unclear. In this study, mice were fed a control diet, high-fat diet (HFD; 60% kcal fat and 20% kcal carbohydrate), or western diet (WD; 40% kcal fat and 43% kcal carbohydrate) and administered with multi-strain AB-Kefir containing six strains of lactic acid bacteria and a Bifidobacterium strain, at 109 CFU per mouse for 10 weeks. Results demonstrated that AB-Kefir reduced body weight gain, glucose intolerance, and hepatic steatosis with a minor influence on gut microbiota composition in HFD-fed mice, but not in WD-fed mice. In addition, AB-Kefir significantly reduced the weight and size of adipose tissues by regulating the expression of CD36, Igf1, and Pgc1 in HFD-fed mice. Although AB-Kefir did not reduce the volume of white adipose tissue, it markedly regulated CD36, Dgat1 and Mogat1 mRNA expression. Moreover, the abundance of Eubacterium_coprostanoligenes_group and Ruminiclostridium significantly correlated with changes in body weight, liver weight, and fasting glucose in test mice. Overall, this study provides important evidence to understand the interactions between probiotics, gut microbiota, and diet in obesity treatment.

The effect of multi-strain probiotics as feed additives on performance, immunity, expression of nutrient transporter genes and gut morphometry in broiler chickens.

ObjectiveThis study was conducted to investigate the effects of dietary multi-strain probiotic (MSP) (Bacillus coagulans Unique IS2 + Bacillus subtillis UBBS14 + Saccharomyces boulardii Unique 28) on performance, gut morphology and expression of nutrient transporter related genes in broiler chickens.MethodsA total of 256 (4×8×8) day-old CARIBRO Vishal commercial broiler chicks of uniform body weight were randomly distributed into four treatments with 8 replicates each and having eight chicks in each replicate. Four dietary treatments were T1 (negative control-basal diet), T2 (positive control-antibiotic bacitracin methylene disalicylate at 20 mg/kg diet), T3 (MSP at 107 colony-forming unit [CFU]/g feed), and T4 (MSP at 108 CFU/g feed).ResultsDuring 3 to 6 weeks and 0 to 6 weeks, the body weight gain increased significantly (p<0.05) in T3 and T4 groups. The feed intake significantly (p<0.05) reduced from T1 to T3 during 0 to 3 weeks and the feed conversion ratio also significantly (p<0.05) improved in T3 and T4 during 0 to 6 weeks. The humoral and cell mediated immune response and the weight of immune organs were also significantly (p<0.05) improved in T3 and T4. However, significant (p<0.05) dietary effects were observed on intestinal histo-morphometry of ileum in T3 followed by T4 and T2. At 14 d post hatch, the relative gene expression of glucose transporter (GLUT5), sodium-dependent glucose transporter (SGLT1) and peptide transporter (PepT1) showed a significant (p<0.05) up-regulating pattern in T2, T3, and T4. Whereas, at 21 d post hatch, the gene expression of SGLT1 and PepT1 was significantly (p<0.05) down-regulated in MSP supplemented treatments T3 and T4.ConclusionThe supplementation of MSP at 107 CFU/g diet showed significant effects with improved performance, immune response, gut morphology and expression of nutrient transporter genes. Thus, the MSP could be a suitable alternative to antibiotic growth promoters in chicken diets.

Effects of Multi-Strain Probiotics on Immune Responses and Metabolic Balance in Helicobacter pylori-Infected Mice.

Chronic inflammation caused by Helicobacter pylori infection increases the risk of developing gastric cancer. Even though the prevalence of H. pylori infection has been decreased in many regions, the development of antibiotic resistance strains has increased the difficulty of eradicating H. pylori. Therefore, exploring alternative approaches to combat H. pylori infection is required. It is well-known that probiotic therapy can improve H. pylori clearance. In this study, H. pylori-infected mice were treated with Lactobacillus fermentum P2 (P2), L. casei L21 (L21), L. rhamnosus JB3 (JB3), or a mixture including the aforementioned three (multi-LAB) for three days. All the lactic acid producing bacteria (LAB) treatments decreased H. pylori loads in the stomach and vacA gene expression, H. pylori specific immunoglobulin (Ig) A, and IgM levels in stomach homogenates, as well as serum levels of interferon-gamma and interleukin-1 beta. The multi-LAB and JB3 treatments further restored the superoxide dismutase and catalase activities suppressed by H. pylori infection. Furthermore, H. pylori infection decreased serum concentrations of 15 kinds of amino acids as well as palmitic acid. The multi-LAB treatment was able to recover the serum levels of alanine, arginine, aspartate, glycine, and tryptophan, which are all important in modulating immune functions. In addition, butyric acid, valeric acid, palmitic acid, palmitoleic acid, stearic acid, and oleic acid levels were increased. In this study, multi-LAB revealed its ability to adjust the composition of metabolites to improve health. To date, the mechanisms underlying how LAB strains crosstalk with the host are not fully understood. Identifying the mechanisms which are regulated by LABs will facilitate the development of effective therapies for infection in the future.

The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials

Irritable bowel syndrome (IBS) is a functional bowel disorder that may involve disturbance of the gastrointestinal microbiota. We performed a systematic review and meta-analysis of the efficacy and safety of probiotics in patients with IBS. We searched the Cochrane Library, PubMed, EMBASE and Web of Science databases up to 1 April, 2019. Randomized controlled trials (RCTs) involving adults with IBS that compared probiotics to placebo or no therapy were eligible for the analysis. Dichotomous symptom data were pooled to calculate the relative risk (RR) with a 95% confidence interval (CI) of remaining symptoms after therapy. Continuous data were pooled using a standardized mean difference (SMD) with the 95% CI. Two reviewers assessed trial quality and extracted data independently. Thirty-five RCTs involving 3,452 patients were included in the analysis. Compared with placebo, patients using probiotics had a lower incidence of persistence of symptoms (RR 0.79, 95% CI 0.70 to 0.89, P< 0.0001). Also, probiotics exerted a beneficial effect on global symptoms and the abdominal pain score (SMD -0.25, 95% CI -0.36 to -0.14, P< 0.00001), bloating score (SMD -0.15, 95% CI -0.27 to -0.03, P=0.01), and flatulence score (SMD -0.20, 95% CI -0.35 to -0.05, P= 0.01). However, patients treated with probiotics had a higher incidence of any adverse event (RR 1.21; 95% CI 1.02 to 1.44). Supplementation with multi-strain probiotics can improve IBS symptoms. Further research is required if probiotics are to be adopted as a treatment for IBS.

Effects of Multi-strain Probiotics with Variable Energy Density Diets on Growth Performance, Nutrient Digestibility, Blood Characteristics, Faecal Microflora, and Noxious Gas Emission in Finishing Pigs

The present study was conducted to investigate the effects of multi-strain probiotics with variable energy density diets on growth performance, nutrient digestibility, blood characteristics, faecal microflora and noxious gas emission in finishing pigs. Eighty [(Landrace × Yorkshire) × Duroc] pigs with initial BW of 79.95±2.49 kg were used in this 6-wk feeding trial. Pigs were allotted to one of 4 dietary treatments in a 2×2 factorial design with two levels of energy density (low or high) and probiotics (0 or 0.02% of diet). There were four replications and five pigs per pen. The pigs fed high energy density diet had better gain: feed ratio (P 0.05). In conclusion, administration of 0.02% multi-strain probiotics exerted beneficial effects on faecal microbial shedding and noxious gas emission irrespective of energy density of the diets.

Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial.

Evidence of a possible connection between gut microbiota and several physiological processes linked to type 2 diabetes is increasing. However, the effect of multi-strain probiotics in people with type 2 diabetes remains unclear. This study investigated the effect of multi-strain microbial cell preparation-also refers to multi-strain probiotics-on glycemic control and other diabetes-related outcomes in people with type 2 diabetes. A randomized, double-blind, parallel-group, controlled clinical trial. Diabetes clinic of a teaching hospital in Kuala Lumpur, Malaysia. A total of 136 participants with type 2 diabetes, aged 30-70years, were recruited and randomly assigned to receive either probiotics (n=68) or placebo (n=68) for 12weeks. Primary outcomes were glycemic control-related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The Lactobacillus and Bifidobacterium quantities were measured before and after intervention as an indicator of successful passage of the supplement through gastrointestinal tract. Intention-to-treat (ITT) analysis was performed on all participants, while per-protocol (PP) analysis was performed on those participants who had successfully completed the trial with good compliance rate. With respect to primary outcomes, glycated hemoglobin decreased by 0.14% in the probiotics and increased by 0.02% in the placebo group in PP analysis (p<0.05, small effect size of 0.050), while these changes were not significant in ITT analysis. Fasting insulin increased by 1.8µU/mL in placebo group and decreased by 2.9µU/mL in probiotics group in PP analysis. These changes were significant between groups at both analyses (p<0.05, medium effect size of 0.062 in PP analysis and small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. Probiotics successfully passedthrough the gastrointestinal tract. Probiotics modestly improved HbA1c and fasting insulin in people with type 2 diabetes.

Effects of multistrain probiotics on growth performance, nutrient digestibility, blood profiles, faecal microbial shedding, faecal score and noxious gas emission in weaning pigs.

This experiment was conducted to investigate the efficacy of multistrain probiotics in weaning pigs. A total of 125 28-day-old weaning pigs [(Landrace×Yorkshire)×Duroc] with an initial average body weight (BW) of 7.26±0.76kg were randomly allotted into 5 treatments, 5 replicate pens/treatment with 5 pigs/pen for 42-day experiment. Dietary treatments were as follows: CON, basal diet; PC1, CON+0.01% multistrain probiotics; PC2, CON+0.03% multistrain probiotics; PC3, CON+0.06% multistrain probiotics; PC4, CON+0.1% multistrain probiotics. On day 14, pigs fed the PC4 diet had higher BW gain than pigs fed the CON diet. On day 42, pigs fed multistrain probiotics supplementation diets had higher BW gain than pigs fed the CON diet. From days 1 to 14, pigs fed the PC2, PC3 and PC4 diets had higher (p<0.05) ADG than pigs fed the CON diet. From day 15 to 42, pigs fed the multistrain probiotics supplementation diets had higher (p<0.05) average daily gain (ADG) and gain: feed ratio (G:F) than pigs fed the CON diet. In the overall period, pigs fed the multistrain probiotics supplementation diets had higher (p<0.05) ADG and pigs fed the PC2 and PC4 diets had higher (p<0.05) G:F than pigs fed the CON diet. On day 42, pigs fed the PC4 diet had higher (p<0.05) apparent total tract digestibility (ATTD) of dry matter (DM), nitrogen (N) and gross energy (GE), faecal Lactobacillus counts and lower (p<0.05) E.coli counts and NH3 emission than pigs fed the CON diet. Pigs fed the multistrain probiotics supplementation diets had lower (p<0.05) H2 S and total mercaptans emissions than pigs fed the CON diet. Conclusions, dietary supplementation with 0.1% probiotics improved growth performance, nutrition digestibility and intestinal microflora balance and decreased faecal noxious gas emissions in weaning pigs.

Effects of Multi Strain Probiotics on Egg Production and Quality in Laying Hens Fed Diets Containing Food Waste Product

Effects of Multi Strain Probiotics on Egg Production and Quality in Laying Hens Fed Diets Containing Food Waste Product

Effects of multistrain probiotics on growth performance, apparent ileal nutrient digestibility, blood characteristics, cecal microbial shedding, and excreta odor contents in broilers

This experiment was conducted to investigate the efficacy of Lactobacillus acidophilus, Bacillus subtilis, and Clostridium butyricum supplementation in broilers. A total of 400 one-day-old mixed sex Ross 308 broilers with an initial average BW of 46 ± 0.5 g were randomly allotted into 4 treatments with 5 replicate pens per treatment and 20 broilers in each pen for 35 d. Dietary treatments were (1) an antibiotic-free diet (CON), (2) CON + 5 mg/kg of avilamycin, (3) CON + 1 × 10(5) cfu of multistrain probiotics/kg of diet (P1), and (4) CON + 2 × 10(5) cfu of multistrain probiotics/kg of diet (P2). Broilers fed the P1 and P2 diets had greater BW gain than broilers fed the CON diet during d 22 to 35 (P = 0.01) and overall (P = 0.02). Feed conversion ratios in P1 and P2 were decreased (P = 0.03) compared with that in CON from d 22 to 35. Ileal digestibility of most essential amino acids, with the exception of His and Phe, were increased (P < 0.05) in P1 and P2 compared with CON. Serum IgA and IgM concentrations in P2 were higher (P < 0.05) than those in CON. The cecal Lactobacillus numbers were increased (P = 0.02), and the counts of Escherichia coli were decreased (P = 0.03) in P1 and P2 compared with CON. Dietary supplementation with multistrain probiotics decreased (P < 0.05) the excreta NH3 content compared with the CON. In conclusion, dietary supplementation with multistrain probiotics improved broiler growth performance, ileal amino acids digestibility, and humoral immunity. Furthermore, the probiotics decreased the cecal numbers of E. coli and decreased the NH3 content of excreta.